Allarity Therapeutics, Inc.

What they do

Allarity developed a Drug Response Predictor (DRP) platform that defines gene-expression signatures predicting cancer cell sensitivity to specific anti-cancer therapeutics. The company has narrowed its portfolio to stenoparib, a dual PARP1/2 and tankyrase inhibitor in-licensed from Eisai with exclusive worldwide rights, and is developing the stenoparib-DRP as a companion diagnostic to select patients. Other assets (dovitinib, Irofulven, LiPlaCis) have been terminated.

Revenue drivers

• Stenoparib (2X-121) — The company's sole remaining drug candidate; no product revenue has been generated from it, and annual revenue was $320,000 in 2025 versus $0 in 2024.
• Stenoparib-DRP companion diagnostic — A gene-expression test intended to select patients likely to benefit from stenoparib; a key U.S. patent was granted with term into April 2042, but it currently produces no revenue.
• Licensing and milestone structure (Eisai) — Allarity owes Eisai up to $94 million in development/regulatory/commercial milestones plus a $50 million one-time sales milestone if annual sales reach $1 billion, and royalties of 5%–15% on escalating sales bands.

Recent performance

Second quarter 2026 revenue was $0.00, following $25,000 in Q1 2026 revenue and $0.00 in both Q1 and Q2 2025. The company reported ending the quarter with $26.9 million in cash and restricted cash, against total assets of $32.1 million, total liabilities of $28.6 million and shareholder equity of $3.5 million at June 30, 2026. Full-year 2025 net loss was $11.2 million versus a $24.5 million loss in 2024. Operating cash flow has been negative every year presented, at -$14.8 million in 2025 and -$17.4 million in 2024.

Strategy

Management is focused solely on stenoparib and its DRP companion diagnostic, having terminated all other programs. In 2025 it initiated a new randomized Phase 2 protocol in platinum-resistant or platinum-ineligible ovarian cancer enrolling 40 patients across two dose levels (600 mg and 800 mg daily, each split twice daily), with all patients providing fresh biopsies to define the DRP score predicting durable benefit. A separate randomized, biomarker-driven trial combining stenoparib with temozolomide in relapsed small cell lung cancer is fully funded by the U.S. Veteran's Administration. The company completed a Phase 3-ready stenoparib API manufacturing campaign in July 2026, ahead of plan, and obtained CLIA certification for its in-house laboratory to run DRP testing internally.

Risks

• No product revenue — Allarity has never generated meaningful product revenue, reporting $0.00 in the most recent quarter and only $320,000 for all of 2025.
• Eisai milestone and royalty obligations — The Eisai license requires up to $94 million in milestones, a $50 million sales milestone at $1 billion annual sales, and royalties up to 15%, and the 10-K states the company may become delinquent in payments to Eisai.
• Persistent cash burn — Operating cash flow was negative $14.8 million in 2025 and negative $17.4 million in 2024, with a $3.5 million shareholder equity cushion at June 30, 2026.
• Clinical and regulatory dependence on one asset — With dovitinib, Irofulven and LiPlaCis terminated, the entire pipeline depends on stenoparib and the stenoparib-DRP, which are still in Phase 2 testing.

Outlook

Management states the completed manufacturing campaign and CLIA-certified in-house laboratory position the company to accelerate stenoparib toward a pivotal, registrational trial and FDA approval following its Fast Track designation. The company cites the granted U.S. patent extending into April 2042 and AACR 2026 data linking higher stenoparib DRP scores to enhanced overall survival as support for DRP-guided patient selection. It ended the quarter with almost $27 million in cash and restricted cash, which management describes as funding continued advancement of stenoparib.